ストックスクリーナーアプリを入手
132.18
3.64%
-4.99
アフターアワーズ：
132.18
前日終値:
$137.17
開ける：
$139.66
24時間の取引高:
329.79K
Relative Volume:
1.06
時価総額：
$4.80B
収益：
$290.51M
当期純損益:
$89.16M
株価収益率:
44.21
EPS:
2.99
ネットキャッシュフロー:
$119.18M
1週間 パフォーマンス:
-20.45%
1か月 パフォーマンス:
-21.40%
6か月 パフォーマンス:
-33.78%
1年 パフォーマンス:
-16.73%
1日の値動き範囲:
$131.71
$140.54
1週間の範囲:
$131.71
$167.21
52週間の値動き範囲:
$131.71
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
名前
Krystal Biotech Inc
セクター
電話
(412) 586-5830
住所
2100 WHARTON STREET, PITTSBURGH, PA
KRYS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
132.18 | 4.80B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-05 | 開始されました | Jefferies | Buy |
| 2024-08-06 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-11-20 | 開始されました | Goldman | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-12 | 開始されました | Citigroup | Buy |
| 2023-09-07 | 開始されました | Berenberg | Buy |
| 2023-04-18 | 開始されました | Stifel | Buy |
| 2023-02-28 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-25 | ダウングレード | Goldman | Buy → Neutral |
| 2022-01-18 | 開始されました | BofA Securities | Buy |
| 2021-07-20 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-18 | 開始されました | B. Riley FBR | Buy |
| 2020-06-04 | 開始されました | Evercore ISI | Outperform |
| 2019-09-24 | 開始されました | Goldman | Neutral |
| 2019-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-24 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-06-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-30 | 開始されました | Guggenheim | Buy |
| 2018-09-11 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Krystal Biotech Inc (KRYS) 最新ニュース
Krystal Biotech, Inc. (KRYS): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
H.C. Wainwright maintains Buy on Krystal Biotech shares - Investing.com Australia
Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates - MSN
Krystal Biotech "insulated" by domestic manufacturingPittsburgh Business Times - The Business Journals
Krystal Biotech (KRYS) Price Target Lowered by Guggenheim | KRYS Stock News - GuruFocus
H.C. Wainwright maintains Buy on Krystal Biotech shares By Investing.com - Investing.com Canada
Krystal Biotech (KRYS) Faces Hurdles After Lowered Price Target | KRYS Stock News - GuruFocus
Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2025 Earnings Call Transcript - Insider Monkey
Krystal Biotech to Present at BofA Securities 2025 Health Care Conference - The Manila Times
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down - MSN
Krystal Biotech (KRYS) Maintains Buy Rating and Price Target | KRYS Stock News - GuruFocus
Krystal Biotech Inc (KRYS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Krystal Biotech Inc (KRYS) Q1 2025 Earnings Call Highlights: Rec - GuruFocus
Krystal Biotech Inc (KRYS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Krystal Biotech Reports Strong Q1 2025 Results - TipRanks
Decoding Krystal Biotech Inc (KRYS): A Strategic SWOT Insight - GuruFocus
Krystal Biotech outlines 2025 global launch strategy with $88.2M Q1 VYJUVEK revenue - MSN
Krystal Biotech’s Earnings Call Highlights Growth and Expansion - TipRanks
Earnings call transcript: Krystal Biotech misses Q1 2025 EPS forecast, stock drops 14% - Investing.com
Krystal Biotech (KRYS) Receives Reiterated Buy Rating and Maintained Price Target | KRYS Stock News - GuruFocus
Krystal Biotech Q1 2025 slides: VYJUVEK revenue up 95% YoY despite sequential dip By Investing.com - Investing.com South Africa
Krystal Biotech is Now Oversold (KRYS) - Nasdaq
Krystal Biotech Q1 2025 slides: VYJUVEK revenue up 95% YoY despite sequential dip - Investing.com India
Krystal Biotech shares tumble as Q1 results miss expectations By Investing.com - Investing.com Nigeria
Krystal Biotech Q1 2025 Earnings: EPS of $1.24 and Revenue of $8 - GuruFocus
KRYSTAL BIOTECH Earnings Results: $KRYS Reports Quarterly Earnings - Nasdaq
Krystal Biotech (KRYS) Reports Q1 Revenue Below Expectations Ami - GuruFocus
Krystal Biotech's Q1 Earnings, Revenue Rise - marketscreener.com
Krystal Biotech, Inc. SEC 10-Q Report - TradingView
Krystal Biotech Announces First Quarter 2025 Financial and Operating Results - The Manila Times
Krystal Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Earnings Flash (KRYS) Krystal Biotech Reports Q1 Revenue $88.2M, vs. FactSet Est of $96.2M - marketscreener.com
Krystal Biotech Presents Promising Gene Therapy at ARVO - TipRanks
Krystal Biotech Q1 2025 Earnings Preview - MSN
Krystal Biotech Inc (KRYS) Q1 2025 Earnings Report Preview: What to Look For - GuruFocus
Krystal Biotech (KRYS) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Chardan Capital Forecasts Krystal Biotech FY2025 Earnings - Defense World
Where are the Opportunities in (KRYS) - news.stocktradersdaily.com
Commit To Purchase Krystal Biotech At $150, Earn 16.3% Annualized Using Options - Nasdaq
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Krystal Biotech shares rise as H.C. Wainwright lifts price target By Investing.com - Investing.com Canada
Krystal Biotech (NASDAQ:KRYS) Given New $240.00 Price Target at HC Wainwright - Defense World
Krystal Biotech’s VYJUVEK gets European approval for DEB treatment - Investing.com
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Benzinga
Krystal Biotech’s VYJUVEK gets European approval for DEB treatment By Investing.com - Investing.com South Africa
Demystifying Krystal Biotech: Insights From 7 Analyst Reviews - Benzinga
Krystal Biotech (KRYS) Price Target Increased to $240 by H.C. Wa - GuruFocus
Krystal Biotech's Vyjuvek gains European approval for rare skin disease treatmentPittsburgh Business Times - The Business Journals
Krystal Biotech gets EU approval for Vyjuvek (KRYS:NASDAQ) - Seeking Alpha
Krystal Biotech Gets EU Approval to Market Treatment for Dystrophic Epidermolysis Bullosa - marketscreener.com
Krystal Biotech Inc (KRYS) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):